On October 7, 2025, Sonoma Pharmaceuticals announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This registration allows the company to manufacture and commercialize Microcyn technology products as cosmetics in the United States. The move expands Sonoma’s regulatory footprint beyond its existing medical device and prescription product approvals.
The Microcyn-based facial spray is a stabilized hypochlorous acid (HOCl) product that leverages the company’s patented Microcyn® technology. By obtaining MoCRA approval, Sonoma can now market the facial spray as a cosmetic, opening a new distribution channel and potential revenue stream in the U.S. cosmetics market. This regulatory milestone is significant because it removes the need for separate cosmetic approvals for each product line.
The announcement was made by Sonoma on October 7, 2025, and was reported in a press release issued by ACCESS Newswire. The MoCRA registration is a material event for investors because it provides a new pathway for product commercialization and potential sales growth. It also signals the company’s ongoing strategy to broaden its product portfolio and market reach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.